Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Solanezumab - Eli Lilly and Company

Drug Profile

Solanezumab - Eli Lilly and Company

Alternative Names: Anti-amyloid-beta monoclonal antibody - Eli Lilly and Company; Anti-Aβ monoclonal antibody - Eli Lilly and Company; LY-2062430

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly; Eli Lilly and Company; Washington University School of Medicine
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 16 Jul 2023 Additional adverse events data from a phase III trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)
  • 08 Jun 2023 Eli Lilly and Company and Alzheimer's Therapeutic Research Institute completes a phase III trial for Alzheimer's disease (Early-stage disease, In the elderly, Preclinical asymptomatic Alzheimer's disease) in Japan, Canada, Australia, USA (IV) (NCT02008357)
  • 08 Mar 2023 Efficacy and adverse events data from a phase III trial in Alzheimer's disease released by Eli Lilly and Company
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top